RLYB: Utang jangka cendhak perusahaan Rallybio Corp

Rallybio Corporation (RLYB) develops unique treatments for rare fetal and hematological pathologies. Historical short-term debt data illustrate the market response, where the current status is 0.00. However, a lack of profitability and costly testing create financial risks. Meanwhile, the company strictly adheres to biosafety standards and environmental regulations within its laboratories.

Short-term debt measures the aggregate of all company liabilities with a maturity of up to twelve months, reflecting current liquidity and default risk. By analyzing the dynamics of short-term debt capital, an investor assesses the ability of Rallybio Corporation (RLYB) to fund clinical developments through grants without allowing a critical increase in borrowings in the absence of stable commercial revenue from drug sales.